SecSonar.com

Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Xeris Biopharma Holdings, Inc. (XERS) is a Biotechnology company based in US with a market capitalization of $1.1B. Revenue grew 43.7% year-over-year and the company generated $27.9M in free cash flow. This page tracks XERS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 394 employees · IPO Jun 21, 2018

Valuation

Valuation & price

$6.24 · as of May 17, 2026 · -37.0% vs 52w high

1945.7

P/E ratio

Latest-FY diluted EPS

77.81

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$9.90$7.30$4.70Jul 25Dec 25Jun 26Jul 7, 25$4.70Jul 9, 25$5.34Jul 11, 25$5.11Jul 15, 25$5.29Jul 17, 25$5.23Jul 21, 25$5.14Jul 23, 25$5.12Jul 25, 25$5.02Jul 29, 25$5.00Jul 31, 25$5.09Aug 4, 25$5.56Aug 6, 25$5.49Aug 8, 25$6.84Aug 12, 25$7.30Aug 14, 25$7.30Aug 19, 25$7.36Aug 21, 25$7.59Aug 25, 25$7.77Aug 27, 25$7.99Aug 29, 25$7.83Sep 3, 25$7.84Sep 5, 25$7.85Sep 9, 25$7.68Sep 11, 25$7.68Sep 15, 25$7.36Sep 17, 25$7.67Sep 19, 25$7.72Sep 23, 25$7.91Sep 25, 25$7.85Sep 29, 25$8.08Oct 2, 25$8.31Oct 6, 25$8.13Oct 8, 25$8.20Oct 10, 25$7.99Oct 14, 25$8.12Oct 16, 25$9.14Oct 20, 25$9.34Oct 22, 25$9.07Oct 24, 25$9.21Oct 28, 25$9.23Oct 30, 25$9.71Nov 3, 25$9.90Nov 5, 25$9.87Nov 7, 25$7.43Nov 11, 25$7.44Nov 14, 25$7.18Nov 18, 25$7.08Nov 20, 25$6.84Nov 24, 25$7.04Nov 26, 25$7.18Dec 1, 25$6.96Dec 3, 25$6.73Dec 5, 25$6.51Dec 9, 25$7.01Dec 11, 25$7.01Dec 15, 25$7.05Dec 17, 25$6.99Dec 19, 25$7.34Dec 23, 25$7.28Dec 26, 25$7.37Dec 31, 25$7.85Jan 5, 26$7.09Jan 7, 26$7.21Jan 9, 26$7.93Jan 13, 26$7.71Jan 15, 26$7.41Jan 20, 26$7.61Jan 22, 26$7.61Jan 26, 26$7.48Jan 28, 26$7.16Jan 30, 26$7.36Feb 3, 26$7.34Feb 5, 26$6.91Feb 9, 26$6.96Feb 11, 26$6.91Feb 17, 26$6.91Feb 19, 26$6.73Feb 23, 26$6.58Feb 25, 26$6.66Feb 27, 26$6.12Mar 3, 26$5.94Mar 5, 26$6.04Mar 9, 26$5.60Mar 11, 26$5.73Mar 13, 26$5.46Mar 17, 26$5.61Mar 19, 26$5.58Mar 23, 26$5.61Mar 25, 26$5.30Mar 27, 26$5.40Apr 1, 26$6.04Apr 6, 26$6.05Apr 8, 26$5.92Apr 10, 26$5.85Apr 14, 26$6.07Apr 16, 26$6.12Apr 20, 26$6.25Apr 22, 26$6.04Apr 24, 26$6.05Apr 28, 26$6.09Apr 30, 26$6.13May 4, 26$6.34May 6, 26$6.37May 8, 26$6.53May 12, 26$6.26May 15, 26$6.24May 19, 26$5.92May 21, 26$6.38May 26, 26$6.26May 28, 26$6.32Jun 1, 26$6.07Jun 3, 26$5.89Jun 5, 26$6.18Jun 9, 26$6.50Jun 11, 26$6.93Jun 15, 26$6.88Jun 17, 26$6.90Jun 22, 26$6.90Jun 24, 26$7.40Jun 30, 26$7.88
$4.7052-week range$9.90
Loading valuation history…

Fundamentals

Key fundamentals

$1.1B

Market cap

43.7%

Revenue growth (YoY)

81.7%

Gross margin

$27.9M

Free cash flow (USD)

-$73.3M

Net debt

Net cash position

9.3%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.1MFY 2017$1.6MFY 2018$2.5MFY 2019$2.7MFY 2020$20.4MFY 2021$49.6MFY 2022$110.2MFY 2023$163.9MFY 2024$203.1MFY 2025$291.8M
$1.1M$291.8M

Free cash flow by year

2016 → 2025

FY 2016$-16.1MFY 2017$-25.4MFY 2018$-57.8MFY 2019$-80.9MFY 2020$-96.6MFY 2021$-103.4MFY 2022$-103.4MFY 2023$-49.3MFY 2024$-37.8MFY 2025$27.9M
-$16.1M$27.9M

Gross margin by year

2021 → 2025

FY 202173.1%FY 202279.5%FY 202382.5%FY 202481.9%FY 202581.7%
73.1%81.7%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $134K · 10b5-1 PlanHecht Beth · See Remarks · $133.9KJul 2, 2026Filing
  • 8-K eventBoard AppointmentJun 30, 2026Filing
  • 8-K eventDebt Exchange AgreementJun 11, 2026Filing
  • Insider sellInsider Sell $91K · 10b5-1 PlanJOHNSON JOHN · Director · $91.4KJun 5, 2026Filing
  • Insider sellInsider Sell $98K · 10b5-1 PlanBORMANN-KENNEDY BARBARA-JEAN ANNE · Director · $97.5KJun 5, 2026Filing
  • Insider sellInsider Sell $122K · 10b5-1 PlanHALKUFF DAWN · Director · $121.9KJun 5, 2026Filing
  • Insider sellInsider Sell $91K · 10b5-1 PlanPERSKY MARLA · Director · $91.4KJun 5, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing
  • Insider sellInsider Sell $101K · 10b5-1 PlanHecht Beth · See Remarks · $101KJun 2, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing

Questions

Frequently asked questions

What is Xeris Biopharma Holdings, Inc.'s market cap?

Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.1B.

What is XERS's P/E ratio?

XERS trades at a price-to-earnings ratio of 1945.7, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is XERS's price-to-book (P/B) ratio?

XERS trades at 77.81 times book value per share.

Are insiders buying XERS stock?

SEC Form 4 filings show no open-market insider buys at Xeris Biopharma Holdings, Inc. in the last 90 days (7 sells).

Same arena

Related companies in Biotechnology

AKTS

Aktis Oncology, Inc.

$1.1B

OPK

OPKO Health, Inc.

$1.1B

ABSI

Absci Corporation

$1.1B

EYPT

EyePoint Pharmaceuticals, Inc.

$1.2B

LXRX

Lexicon Pharmaceuticals, Inc.

$975M

MGTX

MeiraGTx Holdings plc

$962.2M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.